Cladribine for Waldenström's macroglobulinaemia

Cladribine therapy for systemic mastocytosis.

Patients with systemic mastocytosis (SM) can suffer from disabling symptoms related to mast cell mediator release or mast cell infiltration, requiring mast cell eradication. In the present absence of any curative therapy, a recent case report describing the efficacy of cladribine showed promising results. In a pilot study, the efficacy of cladribine (0.10-0.13 mg/kg in a 2-hour infusion, days 1...

Macroglobulinaemia and steatorrhoea.

Treatment of macroglobulinaemia.

Macroglobulinaemia was first described by Waldenstrbm in 1944. It is characterized by an abnormal tendency to bleed, anaemia, and an increased liability to intercurrent infections; cardiac failure may complicate the clinical picture. Hepatosplenomegaly and generalized lymphadenopathy are frequent, and various neurological lesions (Logothetis et al., 1960) and an unusual retinopathy (Coyle et al...

Four Cases of Waldenstroem's Macroglobulinaemia.

The clinical course and pathological features of four cases of Waldenström's macroglobulinaemia are described. One was associated with a localized carcinoma of the bronchus and one with a chromophobe adenoma of the pituitary. Trypsin digest preparations of the retina were examined in two cases, one with severe retinopathy and the other with no clinical evidence of ocular disease, and the findin...

Waldenstrom's macroglobulinaemia--a case report.

A case of Waldenstrom's macroglobulinemia with classical findings of IgM paraproteinaemia and a typical lymphoplasmacytic marrow infiltrate is reported and the treatment of this patient outlined.